Aurinia Pharmaceuticals (AUPH) News Today $8.67 +0.14 (+1.64%) Closing price 04:00 PM EasternExtended Trading$8.68 +0.01 (+0.06%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Charles Schwab Investment Management Inc. Has $5.97 Million Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Charles Schwab Investment Management Inc. cut its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 10.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 665,087 shares of thMarch 25 at 3:18 AM | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Buys 102,195 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Connor Clark & Lunn Investment Management Ltd. increased its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 22.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 556,454 shares of the biotechnMarch 17, 2025 | marketbeat.comInsiders Are Loading Up on These 4 Biotech Stocks NowMarch 11, 2025 | 247wallst.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells $68,350.15 in StockAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) insider Greg Keenan sold 8,305 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the sale, the insider now owns 153,484 shares of the company's stock, valued at $1,263,173.32. This trade represents a 5.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.March 8, 2025 | marketbeat.comGreg Keenan Sells 8,305 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) StockMarch 8, 2025 | insidertrades.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Up 7.1% - Time to Buy?Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Up 7.1% - Here's What HappenedMarch 6, 2025 | marketbeat.comAurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting PointMarch 6, 2025 | finance.yahoo.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CEO Peter Greenleaf Sells 195,593 SharesAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the sale, the chief executive officer now directly owns 1,953,892 shares in the company, valued at approximately $15,631,136. This trade represents a 9.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.March 6, 2025 | marketbeat.comInsider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells 12,239 Shares of StockAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) insider Greg Keenan sold 12,239 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $97,912.00. Following the transaction, the insider now directly owns 161,789 shares of the company's stock, valued at approximately $1,294,312. This represents a 7.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 5, 2025 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CFO Joseph M. Miller Sells 61,859 SharesAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) CFO Joseph M. Miller sold 61,859 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $494,872.00. Following the transaction, the chief financial officer now directly owns 633,515 shares in the company, valued at $5,068,120. This trade represents a 8.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 5, 2025 | marketbeat.comInsider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) COO Sells 65,902 Shares of StockAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) COO Matthew Maxwell Donley sold 65,902 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $527,216.00. Following the completion of the transaction, the chief operating officer now directly owns 739,456 shares in the company, valued at approximately $5,915,648. The trade was a 8.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.March 5, 2025 | marketbeat.comGreg Keenan Sells 12,239 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) StockMarch 5, 2025 | insidertrades.comResults: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMarch 2, 2025 | uk.finance.yahoo.com1AUPH : Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit,...March 1, 2025 | benzinga.comAurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call TranscriptMarch 1, 2025 | seekingalpha.comAurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results, Beats Expectations By $0.04 EPSAurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) (TSE:AUP) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.04. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%.February 28, 2025 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Sees Strong Trading Volume Following Strong EarningsAurinia Pharmaceuticals (NASDAQ:AUPH) Sees Strong Trading Volume Following Strong EarningsFebruary 28, 2025 | marketbeat.comAurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats ExpectationsFebruary 28, 2025 | finance.yahoo.comAurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...February 28, 2025 | finance.yahoo.comRBC Capital Reaffirms Their Buy Rating on Aurinia Pharmaceuticals (AUPH)February 28, 2025 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Warby Parker (WRBY)February 27, 2025 | markets.businessinsider.comAutoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below ExpectationsFebruary 27, 2025 | benzinga.comAurinia Pharmaceuticals reports Q4 EPS 1c, consensus (2c)February 27, 2025 | markets.businessinsider.comAurinia Pharmaceuticals sees 2025 revenue $250M-$260M, consensus $274.4MFebruary 27, 2025 | markets.businessinsider.comAurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate ProgressFebruary 27, 2025 | financialpost.comAurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate ProgressFebruary 27, 2025 | businesswire.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock Holdings Increased by IFP Advisors IncIFP Advisors Inc increased its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 31.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 271,132 shares of the biotechnolFebruary 26, 2025 | marketbeat.comAurinia Pharmaceuticals: There's Still Time For Sales GrowthFebruary 21, 2025 | seekingalpha.comAurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025February 20, 2025 | financialpost.comAurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025February 20, 2025 | financialpost.comAurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025February 20, 2025 | businesswire.comStockNews.com Downgrades Aurinia Pharmaceuticals (NASDAQ:AUPH) to BuyStockNews.com downgraded Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Wednesday.February 19, 2025 | marketbeat.comAurinia Pharmaceuticals (AUPH) Projected to Post Earnings on ThursdayAurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comShort Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Expands By 25.5%Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 9,390,000 shares, an increase of 25.5% from the January 15th total of 7,480,000 shares. Based on an average trading volume of 1,430,000 shares, the days-to-cover ratio is currently 6.6 days.February 15, 2025 | marketbeat.comCompagnie Lombard Odier SCmA Cuts Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Compagnie Lombard Odier SCmA lowered its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 87.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,000 shares of the biotechnology coFebruary 15, 2025 | marketbeat.comAurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on ThursdayAurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports.February 13, 2025 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Cross Below 50-Day Moving Average - What's Next?Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 50 Day Moving Average - Should You Sell?February 11, 2025 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Stock Rating Lowered by StockNews.comStockNews.com downgraded Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday.February 10, 2025 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Sees Large Increase in Short InterestAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 7,480,000 shares, an increase of 29.2% from the December 31st total of 5,790,000 shares. Based on an average daily trading volume, of 1,410,000 shares, the days-to-cover ratio is presently 5.3 days.February 1, 2025 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC lowered its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 88.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,564 shares of theFebruary 1, 2025 | marketbeat.comIs Aurinia Pharmaceuticals Poised for Growth in the Biotech Space?January 14, 2025 | stocknews.comBarclays PLC Increases Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Barclays PLC lifted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 187.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 219,331 shares of the biotechnology compaJanuary 12, 2025 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded by StockNews.com to Strong-Buy RatingStockNews.com upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday.January 9, 2025 | marketbeat.comFranklin Resources Inc. Sells 75,024 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Franklin Resources Inc. cut its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 78.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,253 shares of the biotechnology company's stJanuary 3, 2025 | marketbeat.comBarclays PLC Buys 143,072 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Barclays PLC increased its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 187.6% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 219,331 shares of the biotechnology company's stock after buyingDecember 28, 2024 | marketbeat.comAurinia Pharmaceuticals laying off dozens in Montgomery CountyDecember 24, 2024 | bizjournals.comState Street Corp Has $21.59 Million Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)State Street Corp grew its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 2.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,945,060 shares of the biotechnology company's stock after buyingDecember 24, 2024 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest UpdateAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 6,220,000 shares, a decline of 9.6% from the November 15th total of 6,880,000 shares. Based on an average daily trading volume, of 1,260,000 shares, the days-to-cover ratio is presently 4.9 days.December 15, 2024 | marketbeat.comInsiders Are Loving These 6 Stocks Right NowDecember 15, 2024 | 247wallst.comAurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to "Buy" at StockNews.comStockNews.com cut shares of Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday.December 13, 2024 | marketbeat.com Remove Ads Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Media Mentions By Week AUPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUPH News Sentiment▼1.360.68▲Average Medical News Sentiment AUPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUPH Articles This Week▼23▲AUPH Articles Average Week Remove Ads Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTCT News RNA News ACLX News OGN News ZLAB News RARE News SWTX News AKRO News ALVO News RYTM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUPH) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUPH Stock Free AUPH Stock Alerts